Movement Alert｜Alnylam Pharmaceuticals Rises 5.01% in Regular Trading, Multiple Partnership Catalysts Fuel Rally Amid Biotech Sector Strength

Market Focus07-02 23:01

On July 2, Alnylam Pharmaceuticals rose 5.01% in regular trading, trading at $317.17/share, with turnover of $69.34 million.

The rally was fueled by a series of recent strategic partnership announcements and broader biotech sector strength. Most recently, the company expanded its strategic partnership with Komodo Health to deploy the Marmot AI analytics platform across its customer-facing and broader enterprise functions. Earlier, Alnylam announced a collaboration with Inceptive valued at up to $2 billion, including $30 million upfront, to leverage AI in accelerating RNAi therapeutic discovery. The company also expanded its commercial partnership with Genesis Pharma into four Nordic markets for its RNA interference therapeutics portfolio.

Fundamentally, Alnylam reported strong Q1 results with adjusted EPS of $1.99 versus $1.41 expected, and revenue of $1.17 billion, while reiterating full-year product revenue guidance of $4.90-$5.30 billion. Within the Biotechnology sector, the overall trend was positive, with Moderna up 7.05%, Abivax up 9.45%, Vertex Pharmaceuticals up 4.88%, and Gilead Sciences up 4.06%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198755198?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198755198","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Alnylam Pharmaceuticals Rises 5.01% in Regular Trading, Multiple Partnership Catalysts Fuel Rally Amid Biotech Sector Strength","media":"Market Focus","content":"<p><p>On July 2, Alnylam Pharmaceuticals rose 5.01% in regular trading, trading at $317.17/share, with turnover of $69.34 million.</p><p>The rally was fueled by a series of recent strategic partnership announcements and broader biotech sector strength. Most recently, the company expanded its strategic partnership with Komodo Health to deploy the Marmot AI analytics platform across its customer-facing and broader enterprise functions. Earlier, Alnylam announced a collaboration with Inceptive valued at up to $2 billion, including $30 million upfront, to leverage AI in accelerating RNAi therapeutic discovery. The company also expanded its commercial partnership with Genesis Pharma into four Nordic markets for its RNA interference therapeutics portfolio.</p><p>Fundamentally, Alnylam reported strong Q1 results with adjusted EPS of $1.99 versus $1.41 expected, and revenue of $1.17 billion, while reiterating full-year product revenue guidance of $4.90-$5.30 billion. Within the Biotechnology sector, the overall trend was positive, with Moderna up 7.05%, Abivax up 9.45%, Vertex Pharmaceuticals up 4.88%, and Gilead Sciences up 4.06%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Alnylam Pharmaceuticals Rises 5.01% in Regular Trading, Multiple Partnership Catalysts Fuel Rally Amid Biotech Sector Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Alnylam Pharmaceuticals Rises 5.01% in Regular Trading, Multiple Partnership Catalysts Fuel Rally Amid Biotech Sector Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, Alnylam Pharmaceuticals rose 5.01% in regular trading, trading at $317.17/share, with turnover of $69.34 million.</p><p>The rally was fueled by a series of recent strategic partnership announcements and broader biotech sector strength. Most recently, the company expanded its strategic partnership with Komodo Health to deploy the Marmot AI analytics platform across its customer-facing and broader enterprise functions. Earlier, Alnylam announced a collaboration with Inceptive valued at up to $2 billion, including $30 million upfront, to leverage AI in accelerating RNAi therapeutic discovery. The company also expanded its commercial partnership with Genesis Pharma into four Nordic markets for its RNA interference therapeutics portfolio.</p><p>Fundamentally, Alnylam reported strong Q1 results with adjusted EPS of $1.99 versus $1.41 expected, and revenue of $1.17 billion, while reiterating full-year product revenue guidance of $4.90-$5.30 billion. Within the Biotechnology sector, the overall trend was positive, with Moderna up 7.05%, Abivax up 9.45%, Vertex Pharmaceuticals up 4.88%, and Gilead Sciences up 4.06%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALNY","symbol_name":"阿尔尼拉姆制药公司","start_time":0,"source_url":"","article_id":"1198755198","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198755198","pubTimestamp":1783004471,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, Alnylam Pharmaceuticals rose 5.01% in regular trading, trading at $317.17/share, with turnover of $69.34 million.The rally was fueled by a series of recent strategic partnership...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALNY":"阿尔尼拉姆制药公司"},"translate_title":"动向提示|Alnylam Pharmaceuticals在常规交易中上涨5.01%，多重合作催化剂在生物技术板块走强中推动反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1},"content_text":"On July 2, Alnylam Pharmaceuticals rose 5.01% in regular trading, trading at $317.17/share, with turnover of $69.34 million.The rally was fueled by a series of recent strategic partnership announcements and broader biotech sector strength. Most recently, the company expanded its strategic partnership with Komodo Health to deploy the Marmot AI analytics platform across its customer-facing and broader enterprise functions. Earlier, Alnylam announced a collaboration with Inceptive valued at up to $2 billion, including $30 million upfront, to leverage AI in accelerating RNAi therapeutic discovery. The company also expanded its commercial partnership with Genesis Pharma into four Nordic markets for its RNA interference therapeutics portfolio.Fundamentally, Alnylam reported strong Q1 results with adjusted EPS of $1.99 versus $1.41 expected, and revenue of $1.17 billion, while reiterating full-year product revenue guidance of $4.90-$5.30 billion. Within the Biotechnology sector, the overall trend was positive, with Moderna up 7.05%, Abivax up 9.45%, Vertex Pharmaceuticals up 4.88%, and Gilead Sciences up 4.06%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198755198","isCrawlerRequest":true}